Myricx Bio Raises $115M in Series A to Advance ADC With Lilly and Novo Backing

Myricx Bio announced Monday that it has netted a £90 million ($115.5 million) Series A investment round to expand its antibody-drug conjugate platform and advance its pipeline into the clinic.